Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

New Strategy For Inhibiting Ras Oncogene

German team finds potential anticancer agent that blocks RAS protein activation

by Stu Borman
May 27, 2013 | A version of this story appeared in Volume 91, Issue 21

[+]Enlarge
Credit: Nature
Structural analysis of the interaction between this inhibitor (stick structure) and PDEδ (space-filling representation) led the Max Planck group to deltarasin.
A depiction of an inhibitor (stick structure) and PDEd (space-filling representation) that led a Max Planck group to deltarasin.
Credit: Nature
Structural analysis of the interaction between this inhibitor (stick structure) and PDEδ (space-filling representation) led the Max Planck group to deltarasin.

Fighting cancer with a new approach to inhibiting the Ras oncogene pathway has a chance to succeed where others have failed. Aberrant Ras signaling turns on many cancers, so researchers have been trying to inhibit the Ras pathway for decades. But no inhibitor of Ras oncoprotein, Ras’s gene product, has survived clinical trials. The protein PDEδ helps shepherd Ras oncoprotein to cell membranes, where its signaling becomes activated. Now, Alfred Wittinghofer, Philippe I. H. Bastiaens, and Herbert Waldmann of the Max Planck Institute of Molecular Physiology, in Dortmund, Germany, and coworkers have identified an inhibitor, deltarasin, that blocks PDEδ-Ras interactions in vitro and reduces tumor growth in mice (Nature 2013, DOI: 10.1038/nature12205). They used screening methods to find compounds that block PDEδ-Ras interactions, combined two of the compounds, and optimized the combination to create deltarasin. The University of Utah’s Wolfgang Baehr, whose group has studied PDEδ, says deltarasin’s ability to inhibit tumor growth in mice “is clearly a success,” but side effects have yet to be evaluated. The Max Planck group is working with Lead Discovery Center, also in Dortmund, to test and improve deltarasin.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.